The DCT OS Report: More than 95% of biopharma executives say we're not going back to a site-based-only development model. Learn more

The Decentralized Clinical Trial Operating System
A requisite, technology-first platform with limitless configurations to enable clinical research.

With more than 95% of biopharma executives saying the industry won't go back to a pre-pandemic level of site-based clinical trial development, Decentralized Clinical Trials are here to stay.
But while biopharma expects the volume of DCTs to increase, most of them lack the internal capabilities to activate and operationalize.
This report explores the changing clinical research landscape and provides original data on biopharma's experiences and perceptions of decentralized clinical trials.